Document is current

Article History

Received: 10 June 2024

Accepted: 17 September 2024

First Online: 27 September 2024

Declarations

:

: The studies involving human participants were reviewed and approved by the Ethics Committee of Shenzhen Children’s Hospital. Written informed consent to participate in this study was provided by the participants’ legal guardian.

: We assure that the data presented here was not published elsewhere and the article has not been submitted to any other journal. We give our consent for the publication of the manuscript “Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China”.

: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Patients accessed canakinumab on their own expenses and without any company participation.